Compare CALM & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | DYN |
|---|---|---|
| Founded | 1957 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | CALM | DYN |
|---|---|---|
| Price | $69.55 | $16.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $68.33 | $34.33 |
| AVG Volume (30 Days) | 833.8K | ★ 2.1M |
| Earning Date | 01-06-2027 | 11-05-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,911,632,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $60.13 | $14.00 |
| 52 Week High | $95.25 | $27.31 |
| Indicator | CALM | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 41.96 |
| Support Level | $60.91 | $14.43 |
| Resistance Level | $80.00 | $19.48 |
| Average True Range (ATR) | 2.82 | 0.93 |
| MACD | 0.65 | -0.17 |
| Stochastic Oscillator | 80.38 | 8.54 |
Cal-Maine Foods Inc is an egg company in the U.S. Its shell egg portfolio includes conventional, specialty, cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs. The Company operates through the Conventional Shell Eggs, Specialty Shell Eggs and Prepared Foods segments, with Conventional Shell Eggs generating maximum revenue. The Conventional Shell Eggs segment consists mainly of the production, grading, packaging, marketing and distribution of conventional shell eggs, including Sunups and Sunny Meadow. The Company sells its products to grocery store chains, club stores, independent supermarkets, and foodservice distributors serving restaurants, convenience stores, healthcare and education facilities, and hotels throughout the U.S.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.